Greg Frank, PhD

Greg Frank is Director, Global Public Policy with Merck & Co., where he leads global antimicrobial resistance (AMR), influenza, and therapeutic pandemic preparedness policy. Previously, Dr. Frank served as Senior Director for Infectious Disease Policy at the Biotechnology Innovation Organization (BIO), where he led BIO’s work on AMR, vaccine regulatory and reimbursement policy, and other infectious disease issues. Before joining BIO, he led science and diagnostics policy at the Infectious Diseases Society of America (IDSA). He serves on several national and international advisory bodies focused on AMR and pandemic preparedness, including the National Academies Forum on Microbial Threats, the Leadership Council of the National Institute of Antimicrobial Resistant Research and Education (NIAMRRE), and the expert advisory committee for the Partnership to Fight Infectious Diseases. He is a board member of the AMR Industry Alliance, the INTREPID Alliance, and is a member of the World Economic Forum Global Future Council on Tackling AMR. His prior advisory roles include membership on the U.S. Presidential Advisory Committee on Combating Antibiotic-Resistant Bacteria (PACCARB) and participation on expert committees for the Access to Medicine Foundation AMR Benchmark and the Global AMR R&D Hub. Dr. Frank holds a Ph.D. in immunology from the University of Pittsburgh and completed his postdoctoral training at the National Institute of Allergy and Infectious Diseases (NIAID).